Recursion's platform has been designed to handle a wide range of therapeutic areas using the same technology stack. The company also leverages modular designs and consistent protocols to assist with ...

Earnings call Recursion ended Q3 2025 with $785M in cash and no financing needs through 2027, aided by a 35% expense reduction and $40M in partnership inflows YTD. A $30M milestone from Roche ...